Moderna MRNA
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Moderna (MRNA) Core Market Data and Business Metrics
Latest Closing Price
$27.72Price-Earnings Ratio
-2.99Total Outstanding Shares
385.82 Million SharesDividend
No dividendSIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
325 Binney Street, Cambridge, MA, 02142
Historical Stock Splits
If you bought 400 shares of MRNA before July 22, 2010, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| August 3, 2017 | 1-for-10 (Reverse Split) |
| December 23, 2011 | 1-for-10 (Reverse Split) |
| July 22, 2010 | 1-for-4 (Reverse Split) |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 11,271,564 Shares | 4.16 | 3/14/2025 | 46,881,859 Shares |
| 11,837,325 Shares | 3.81 | 2/28/2025 | 45,063,081 Shares |
| 13,226,877 Shares | 3.2 | 2/14/2025 | 42,296,108 Shares |
| 12,117,430 Shares | 3.35 | 1/31/2025 | 40,600,489 Shares |
| 12,865,489 Shares | 3.34 | 1/15/2025 | 43,006,951 Shares |
| 8,631,499 Shares | 4.38 | 12/31/2024 | 37,847,737 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $-3.00 Billion |
| Net Cash Flow From Financing Activities, Continuing | $56 Million |
| Net Cash Flow From Operating Activities, Continuing | $-3.00 Billion |
| Net Cash Flow From Financing Activities | $56 Million |
| Net Cash Flow, Continuing | $-999 Million |
| Net Cash Flow From Investing Activities, Continuing | $1.95 Billion |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Parent | $-3.56 Billion |
| Income Tax Expense/Benefit, Deferred | $-1 Million |
| Diluted Earnings Per Share | $-9.28 |
| Operating Expenses | $5.72 Billion |
| Income/Loss From Equity Method Investments | $-52 Million |
| Research and Development | $4.54 Billion |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $-3.45 Billion |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-3.45 Billion |
| Comprehensive Income/Loss | $-3.45 Billion |
| Other Comprehensive Income/Loss Attributable To Parent | $113 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Liabilities And Equity | $14.14 Billion |
| Wages | $312 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
| Equity Attributable To Parent | $10.90 Billion |
| Noncurrent Liabilities | $1.03 Billion |
| Other Current Assets | $7.98 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||